Ivonescimab Shows Promising Overall Survival Results in NSCLC Treatment at WCLC 2026
A groundbreaking study presented at the World Conference on Lung Cancer 2026 reveals that Ivonescimab significantly improves overall survival rates in patients with PD-L1-positive non-small cell lung cancer compared to Pembrolizumab. This advancement could reshape first-line treatment protocols for NSCLC globally.